Status:
UNKNOWN
Spleen-ARFI-assisted-Portal-Hypertension-Evaluation-Study (SAPHES)
Lead Sponsor:
University of Ulm
Conditions:
Hypertension, Portal
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study evaluates correlation in changes of HVPG-pressure values and stiffness values (ARFI) for spleen and liver and flow-volume values in Portal vein in patients with liver cirrhosis/Portal Hyper...
Detailed Description
Portal Hypertension is the most important risk factor for development of liver cirrhosis-linked complications (e.g. ascites, variceal bleeding, hepatocellular carcinoma, etc.). The invasive HVPG-techn...
Eligibility Criteria
Inclusion
- liver cirrhosis
- portal hypertension
- indication to beta-blocker-therapy
Exclusion
- contraindication to beta-blocker-therapy
- HVPG-measurement not feasible
- portal vein thrombosis
- hematologic underlying disease as the source for enlarged/stiff spleen or liver
Key Trial Info
Start Date :
January 10 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT03315767
Start Date
January 10 2017
End Date
December 1 2018
Last Update
October 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum Ulm
Ulm, Germany